GNTA - Genenta Science • Financials

Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.

Complete and updated financials table with all primary indicators: Net Income, Revenue, EBITDA, Margin, ROE, Dividends

Year	Revenue	EBITDA	Net Inc	Net Mrg	EPS	Equity	ROE	Net Debt Aj	ND/EBITDA Aj	OCF Aj	Capex	FCF	Free Aj	Buyback	Dividend	Payout	DY
12/2019	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2020	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2021	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2022	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2023	0	-13	-	0%	L	23	L	-21	-	-13	-0	0	-13	0	0	-	-
12/2024	0	-10	-	0%	0.03	13	5%	-13	-	-7	-0	0	-7	0	0	-	-
12/2025	0	-8	-	0%	L	26	L	-24	-	-9	-0	26	-9	0	0	-	-

To see all financials—including updated, you must be Premium.